Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Bioconjugate Chemistry|December 22, 2009
Inhibiting tumor growth by targeting tumor vasculature with galectin-1 antagonist anginex conjugated to the cytotoxic acylfulvene, 6-hydroxylpropylacylfulveneRuud P M Dings, Emily S Van Laar, Melissa Loren, et al.
Biochemical Pharmacology|February 5, 2003
Apoptosis induction by the dual-action DNA- and protein-reactive antitumor drug irofulven is largely Bcl-2-independentMaryanne C S Herzig, Alex V Trevino, Huiyun Liang, et al.
Cancer Letters|April 2, 2008
Ovarian tumor growth regression using a combination of vascular targeting agents anginex or topomimetic 0118 and the chemotherapeutic irofulvenRuud P M Dings, Emily S Van Laar, Jeremy Webber, et al.
Investigational New Drugs|February 9, 2013
Polycationic calixarene PTX013, a potent cytotoxic agent against tumors and drug resistant cancerRuud P M Dings, Joseph I Levine, Susan G Brown, et al.
Anticancer Research|October 28, 2015
Evaluation of 111In-labeled Anginex as Potential SPECT Tracer for Imaging of Tumor AngiogenesisTiemen R Van Mourik, Tilman Läppchen, Raffaella Rossin, et al.
Investigational New Drugs|July 14, 2007
A phase I and pharmacokinetic study of irofulven and capecitabine administered every 2 weeks in patients with advanced solid tumorsJérôme Alexandre, Carmen Kahatt, Frédérique Bertheault-Cvitkovic, et al.
Investigational New Drugs|May 10, 2006
A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumorsWerner Hilgers, Sandrine Faivre, Stéphanie Chieze, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2004
Characterization and multiparameter analysis of visual adverse events in irofulven single-agent phase I and II trialsEric Raymond, Carmen Kahatt, Marie Hélène Rigolet, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 27, 2004
Phase I and pharmacokinetic study of irofulven administered weekly or biweekly in advanced solid tumor patientsJérôme Alexandre, Eric Raymond, Mahmoud Ould Kaci, et al.
Pageof 2